Skip to main content

Advertisement

Table 3 Correlation between Braf/p300 staining and tumor size, and ulceration status in 327 melanoma patients

From: A combination of p300 and Braf expression in the diagnosis and prognosis of melanoma

  Tumor size  
  ≤ 2 mm > 2 mm p-value*
Braf    
Low 38 (41.8%) 25 (24.5%) 0.011
High 53 (58.2%) 77 (75.5%)  
Nuclear p300    
Low 33 (36.3%) 43 (42.2%) 0.403
High 58 (63.7%) 59 (57.8%)  
Cytoplasmic p300    
Low 55 (60.4%) 46 (45.1%) 0.033
High 36 (39.6%) 56 (54.9%)  
Braf and nuclear p300    
Low Braf and low p300 11 (12.1%) 13 (12.7%) 0.035
Low Braf and high p300 27 (29.7%) 13 (12.7%)  
High Braf and low p300 22 (24.2%) 30 (29.4%)  
High Braf and high p300 31 (34.1%) 46 (45.1%)  
Braf and cytoplasmic p300    
Low Braf and low p300 22 (24.2%) 18 (17.6%) 0.001
Low Braf and high p300 16 (17.6%) 7 (6.9%)  
High Braf and low p300 33 (36.2%) 28 (27.5%)  
High Braf and high p300 20 (22.0%) 49 (48.0%)  
  Ulceration status  
  Absent Present  
Braf    
Low 53 (36.8%) 10 (20.4%) 0.034
High 91 (63.2%) 39 (79.6%)  
Nuclear p300    
Low 55 (38.2%) 21 (42.9%) 0.564
High 89 (61.8%) 28 (57.1%)  
Cytoplasmic p300    
Low 79 (54.9%) 22 (44.9%) 0.223
High 65 (45.1%) 27 (55.1%)  
Braf and nuclear p300    
Low Braf and low p300 18 (12.5%) 6 (12.2%) 0.199
Low Braf and high p300 35 (24.3%) 5 (10.2%)  
High Braf and low p300 37 (25.7%) 15 (30.6%)  
High Braf and high p300 54 (37.5%) 23 (46.9%)  
Braf and cytoplasmic p300    
Low Braf and low p300 32 (20.8%) 8 (16.3%) 0.119
Low Braf and high p300 21 (13.6%) 2 (4.1%)  
High Braf and low p300 47 (30.5%) 14 (28.6%)  
High Braf and high p300 54 (35.1%) 25 (51.1%)  
  1. *- χ2 test.